GlobeNewswire Inc.··Pomerantz LlpNektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure
Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.
NKTRsecurities fraudclass action lawsuit